跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6 条关于
“SteadyTeq”
全部
6
临床试验
0
药物
0
机构
0
资讯
6
2年前
Teva and Medincell Announce Positive Phase 3 Efficacy Results for TEV-749 in Schizophrenia Treatment
去年
Teva Raises UZEDY Revenue Outlook to $190-200M as Medincell's Olanzapine Injectable Advances Toward FDA Filing
去年
Teva and MedinCell's Long-Acting Risperidone Injection Expands Global Reach with Canadian Approval
去年
Teva's TEV-749 Shows Promise in Schizophrenia Treatment with No PDSS Incidence
12个月前
Teva's Olanzapine LAI Shows No PDSS Events in 56-Week Phase 3 Trial, Paving Way for First Long-Acting Olanzapine Treatment
20小时前
Teva's Once-Monthly Subcutaneous Olanzapine LAI TEV-'749 Shows High Stabilization and Low Relapse in Phase 3 SOLARIS Post Hoc Data